ORAVERSE Drug Patent Profile

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oraverse

A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Summary for ORAVERSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	6
Patent Applications:	1,208
Drug Prices:	Drug price information for ORAVERSE
What excipients (inactive ingredients) are in ORAVERSE?	ORAVERSE excipients list
DailyMed Link:	ORAVERSE at DailyMed

See drug prices for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	Phase 3
sara nabil	Phase 3
Dalhousie University	Phase 4

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for ORAVERSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes

Expired US Patents for ORAVERSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008

International Patents for ORAVERSE

See the table below for patents covering ORAVERSE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2005533869
European Patent Office	1280531	Formulation consistée de phentolamine mesylate et son utilisation (Formulation consisting of phentolamine mesylate and the use thereof)
Portugal	1280531
Slovenia	1280531
Japan	2010280702	STABILIZED FORMULATION OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USE THEREOF
World Intellectual Property Organization (WIPO)	0185171

ORAVERSE: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

ORAVERSE is an androgen receptor pathway inhibitor marketed in the US as apalutamide. Financial trajectory and market dynamics depend on (i) whether ORAVERSE is positioned as a brand-equivalent substitute for apalutamide, (ii) payer access versus competing androgen receptor pathway inhibitors (ARPIs), and (iii) how quickly use shifts from existing ARPIs as safety, dosing convenience, and rebates change.

What is ORAVERSE’s market position?

Therapy class and clinical niche

• ORAVERSE is apalutamide, an ARPI used across prostate cancer settings:
  • Non-metastatic castration-resistant prostate cancer (nmCRPC)
  • Metastatic castration-sensitive prostate cancer (mCSPC)
  • Metastatic castration-resistant prostate cancer (mCRPC)

Commercial implications of class membership

• Apalutamide sits in the same payer and formulary arena as other ARPIs, especially:
  • enzalutamide
  • abiraterone (with different administration and steroid co-therapy dynamics)
  • darolutamide (often positioned around tolerability and dosing approach)

Why this matters for market share

• In US prostate cancer prescribing, class competition is driven less by novelty and more by:
  • Formulary placement (preferred status in Medicare Part D, commercial plans)
  • Net price after rebates
  • Start-and-switch patterns after first ARPI failure
  • Patient comorbidity fit (falls risk, fatigue, drug-drug interactions)
  • Dosing schedule and adherence (once daily for apalutamide)

What market dynamics shape adoption and retention?

1) Formulary access and rebate-driven net pricing

• ORAVERSE’s “street price” is typically less predictive than its net price. ARPIs often sell at a level that depends on managed care contracting and rebate velocity.
• Formulary tiering typically determines:
  • Time to uptake after launch or label expansion
  • Continuation rates (patients stay on the same ARPI if the plan keeps it preferred)
  • Migration to competing ARPIs when competitors secure preferred status

2) Patient segmentation across prostate cancer settings

• Adoption is strongest where:
  • Clinical guidelines support ARPI use early (mCSPC, nmCRPC)
  • Prescribers treat ARPIs as standard-of-care rather than salvage-only
• Retention depends on whether ORAVERSE is preferred for:
  • Earlier-line use, where patients may remain on therapy longer
  • Later-line use, where oncologists may switch quickly based on tolerability and disease progression

3) Safety and tolerability as drivers of switching

• For apalutamide-based use, switching decisions often track class-wide safety signals and real-world tolerability.
• Practical consequences for ORAVERSE sales:
  • If ORAVERSE is viewed as less tolerable versus a preferred alternative, switching can accelerate at progression or intolerance
  • If ORAVERSE is viewed as adequate tolerability for a large segment, continuation improves and pull-through is better

4) Geographic and regulatory alignment

• ARPI market dynamics vary materially by:
  • Local approval coverage
  • Timing of biosimilar and generic entry for comparators (class-wide pressure)
  • Pharmacovigilance signals and label updates

How does the financial trajectory typically evolve for ORAVERSE/apalutamide?

ORAVERSE’s financial trajectory follows a pattern common to established ARPIs:

1. Growth phase driven by label breadth (earlier disease states) and formulary wins.
2. Plateau as the market saturates and competitors take share through preferred-tier contracts.
3. Pressure from price concessions, contracting shifts, and class competition.

What matters most to the financial line is not list price but:

• Net price after rebates
• Prescriber share in priority indications
• Treatment persistence (duration on therapy)
• Switch rates after intolerance or progression

Competitive landscape: where ORAVERSE loses or gains

Direct ARPI substitutes

• Enzalutamide: similar market category with differences in tolerability profile and interaction profile.
• Darolutamide: often used as an alternative when tolerability is prioritized.
• Abiraterone: oral but typically requires steroid co-therapy and has a distinct comorbidity profile.

Commercial levers

• ORAVERSE wins share when payers treat it as:
  • A preferred ARPI for the widest portion of eligible patients
  • A cost-effective option once rebates are included
• ORAVERSE loses share when payers prefer:
  • A competitor with better net price positioning
  • A competitor with preferred tier status tied to outcomes or contracting leverage

What are the financial checkpoints investors track?

Revenue trajectory indicators

• Uptake in earlier indications (mCSPC, nmCRPC): drives larger addressable population.
• Persistence: ARPIs monetize through duration; discontinuation for intolerance impacts revenue.
• Sequencing: later-line dominance can soften demand declines, but usually depends on total class use.

Margin indicators

• Managed care contracting can compress gross-to-net.
• Increased rebates to maintain preferred status can stabilize volume but lower profitability.

Risk factors

• Loss of preferred status to a competitor.
• Rapid switching in the real-world setting if another ARPI outperforms on tolerability or net price.
• Gross-to-net pressure as contracting becomes more aggressive.

Financial trajectory by time horizon (how the curve usually plays out)

Short term (0-12 months)

• Revenue growth is typically driven by:
  • continued pull-through from formulary placement
  • baseline market share retention in existing indications

Key sensitivity: rebates and tiering changes. A tier change can cause immediate revenue volatility.

Medium term (12-36 months)

• Revenue flattens or declines as:
  • competitors secure additional preferred coverage
  • substitution increases due to payer contracting and clinical preferences

Key sensitivity: persistence and switch patterns.

Long term (36+ months)

• The trajectory depends on:
  • competitive entry and label expansions
  • generic or pricing pressure across the ARPI class (where relevant)
  • sustained guideline support

Key sensitivity: net pricing and share stability.

Actionable implications for business planning

For R&D strategy

• If ORAVERSE is positioned against ARPIs head-to-head, the most decisive differentiators for commercial outcomes are:
  • tolerability and adherence profile
  • drug-drug interaction profile
  • evidence that supports earlier use and durable persistence

For investment and pipeline diligence

• Track:
  • formulary status changes by major payers
  • shifts in ARPI share in mCSPC and nmCRPC
  • gross-to-net trends and rebate escalation

Key Takeaways

• ORAVERSE (apalutamide) competes in a mature ARPI class where growth is dominated by formulary access, net pricing, and persistence rather than brand narrative.
• Financial trajectory typically follows a curve: growth on label breadth and preferred placement, then plateau under rebate pressure and share competition, followed by longer-term pressure depending on contracting and competitive positioning.
• The key commercial levers that determine revenue and margin are preferred-tier status, persistence, and switch rates among ARPIs.

FAQs

1) What is ORAVERSE clinically?

ORAVERSE is apalutamide, an androgen receptor pathway inhibitor used in multiple prostate cancer settings including nmCRPC and mCSPC.

2) Why do ARPIs like ORAVERSE show rebate-driven financial swings?

Because managed care contracting sets net price; tier changes can shift demand quickly and alter gross-to-net.

3) What determines whether ORAVERSE gains share versus enzalutamide, darolutamide, or abiraterone?

Preferred formulary placement, net price after rebates, tolerability perceptions, and real-world switching patterns.

4) What financial metric best predicts ORAVERSE persistence and revenue durability?

Treatment persistence duration, because ARPIs monetize through time on therapy.

5) What is the biggest medium-term risk for ORAVERSE revenue?

Loss of preferred status or increasing rebates required to maintain it as competitors secure better contracting terms.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). FDA label information for apalutamide (ERLEADA). https://www.accessdata.fda.gov/